Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Cholangiocarcinoma 2Bile Duct Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Lung Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1

Interventions

camrelizumab 3pembrolizumab 2Radiosurgery 2sinoporphyrin sodium 1penpulimab 1apatinib 1Tramadol 1S 1 (combination) 1Poly(ADP-ribose) Polymerase Inhibitors 1Photochemotherapy 1Pemetrexed 1Paclitaxel 1Morphine 1Injections 1Immune Checkpoint Inhibitors 1130-nm albumin-bound paclitaxel 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Parkinson Disease 4, Autosomal Dominant Lewy Body × 1-phenyl-3,3-dimethyltriazene × Clear all
NCT05386056 2022-11-28

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Peking University

Phase 2 Unknown
54 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡